Anshul Maheshwari Sells 1,414 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 1,414 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $16.35, for a total transaction of $23,118.90. Following the sale, the chief financial officer now directly owns 200,367 shares in the company, valued at $3,276,000.45. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Friday, August 16th, Anshul Maheshwari sold 2,418 shares of SI-BONE stock. The shares were sold at an average price of $13.87, for a total value of $33,537.66.

SI-BONE Trading Down 2.6 %

NASDAQ SIBN opened at $15.83 on Friday. The company has a quick ratio of 8.12, a current ratio of 9.17 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $652.28 million, a P/E ratio of -14.52 and a beta of 1.22. SI-BONE, Inc. has a 52-week low of $11.76 and a 52-week high of $23.25. The firm has a 50-day moving average price of $15.02 and a 200 day moving average price of $15.18.

SI-BONE (NASDAQ:SIBN) last issued its earnings results on Monday, August 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. SI-BONE had a negative return on equity of 24.27% and a negative net margin of 27.10%. The business had revenue of $39.97 million during the quarter, compared to the consensus estimate of $38.95 million. During the same period in the prior year, the business posted ($0.30) EPS. Equities research analysts expect that SI-BONE, Inc. will post -0.89 EPS for the current year.

Institutional Trading of SI-BONE

Several hedge funds and other institutional investors have recently made changes to their positions in SIBN. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of SI-BONE by 14.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,541 shares of the company’s stock worth $179,000 after acquiring an additional 1,106 shares during the period. Russell Investments Group Ltd. raised its position in SI-BONE by 421.8% during the fourth quarter. Russell Investments Group Ltd. now owns 112,441 shares of the company’s stock worth $2,360,000 after acquiring an additional 90,892 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of SI-BONE in the fourth quarter valued at about $6,721,000. Amalgamated Bank increased its stake in shares of SI-BONE by 12.9% during the 4th quarter. Amalgamated Bank now owns 5,877 shares of the company’s stock worth $123,000 after purchasing an additional 673 shares in the last quarter. Finally, Lisanti Capital Growth LLC increased its stake in shares of SI-BONE by 51.2% during the 4th quarter. Lisanti Capital Growth LLC now owns 51,915 shares of the company’s stock worth $1,090,000 after purchasing an additional 17,585 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SIBN. Needham & Company LLC lowered their target price on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Morgan Stanley reduced their price target on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Finally, Truist Financial dropped their price objective on SI-BONE from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $23.00.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.